NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

NCT01220934

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Gastric Cancer

Countries: Germany

This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients, \>/=18 years of age
* Histologically confirmed advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) with locally advanced and/or metastatic disease
* HER2-positive tumor
* Patients who are eligible for treatment with Herceptin according to the judgment of the physician

Exclusion Criteria:

* Unwilling or unable to sign informed consent form
* Any contraindications, interactions and incompatibilities to Herceptin

Locations (1)

Frankfurt, Germany